Log in

Relevant bibliographies by topics / DNA Binding Anticancer Drugs / Journal articles

To see the other types of publications on this topic, follow the link: DNA Binding Anticancer Drugs.

Journal articles on the topic 'DNA Binding Anticancer Drugs'

Author: Grafiati

Published: 4 June 2021

Last updated: 7 September 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'DNA Binding Anticancer Drugs.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Baguley, Bruce C., Catherine J. Drummond, Ying Yi Chen, and Graeme J. Finlay. "DNA-Binding Anticancer Drugs: One Target, Two Actions." Molecules 26, no. 3 (2021): 552. http://dx.doi.org/10.3390/molecules26030552.

Full text

Abstract:

Amsacrine, an anticancer drug first synthesised in 1970 by Professor Cain and colleagues, showed excellent preclinical activity and underwent clinical trial in 1978 under the auspices of the US National Cancer Institute, showing activity against acute lymphoblastic leukaemia. In 1984, the enzyme DNA topoisomerase II was identified as a molecular target for amsacrine, acting to poison this enzyme and to induce DNA double-strand breaks. One of the main challenges in the 1980s was to determine whether amsacrine analogues could be developed with activity against solid tumours. A multidisciplinary

APA, Harvard, Vancouver, ISO, and other styles

2

Marchini, Sergio, Massimo Broggini, Cristiana Sessa, and Maurizio D’Incalci. "Development of distamycin-related DNA binding anticancer drugs." Expert Opinion on Investigational Drugs 10, no. 9 (2001): 1703–14. http://dx.doi.org/10.1517/13543784.10.9.1703.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Farmanzadeh, Davood, and Meysam Najafi. "Benzimidazole derivatives as anticancer drugs: A theoretical investigation." Journal of Theoretical and Computational Chemistry 14, no. 03 (2015): 1550018. http://dx.doi.org/10.1142/s0219633615500182.

Full text

Abstract:

In this study the anticancer properties of a series of benzimidazole drugs 1–9 and their interactions with DNA base pairs were investigated. The obtained theoretical results for anticancer activity of synthesized drugs 1–5 were compared to corresponding published experimental results. Based on theoretical and published experimental anticancer scales, drugs 2 and 4 have higher anticancer activity among drugs 1–5. Obtained results reveal that interactions of studied drugs with DNA base pairs are energetically favorable and solvent and electric field (EF) increase the binding energies in comparis

APA, Harvard, Vancouver, ISO, and other styles

4

Wilmańska, Dorota, Malgorzata Czyz, Kazimierz Studzian, Mariola K. Piestrzeniewicz, and Marek Gniazdowski. "Effects of Anticancer Drugs on Transcription in vitro." Zeitschrift für Naturforschung C 56, no. 9-10 (2001): 886–91. http://dx.doi.org/10.1515/znc-2001-9-1034.

Full text

Abstract:

AbstractThe effects of DNA interacting drugs on: (1) total RNA synthesis catalyzed by E.coli and T7 RNA polymerase; (2) synthesis of the initiating dinucleotide (pppApU) by E .coli RNA polymerase (“abortive initiation“); (3) elongation of RNA chains synthesized by T7 RNA polymerase on pT7-7 plasmid DNA bearing T7 RNA polymerase promoter ϕ 10 with human Cu/Zn superoxide dismutase coding sequence, (4) interaction of transcription factor Sp1 and its binding site were studied. Intercalating ligands which form quickly dissociating complexes with DNA (anthracyclines, proflavine, ethidium bromide) ar

APA, Harvard, Vancouver, ISO, and other styles

5

Jia, Shuailong, Runjing Wang, Kui Wu, Hongliang Jiang, and Zhifeng Du. "Elucidation of the Mechanism of Action for Metal Based Anticancer Drugs by Mass Spectrometry-Based Quantitative Proteomics." Molecules 24, no. 3 (2019): 581. http://dx.doi.org/10.3390/molecules24030581.

Full text

Abstract:

The discovery of the anticancer activity of cisplatin and its clinical application has opened a new field for studying metal-coordinated anticancer drugs. Metal-based anticancer drugs, such as cisplatin, can be transported to cells after entering into the human body and form metal–DNA or metal–protein adducts. Then, responding proteins will recognize adducts and form stable complexes. The proteins that were binding with metal-based anticancer drugs were relevant to their mechanism of action. Herein, investigation of the recognition between metal-based anticancer drugs and its binding partners

APA, Harvard, Vancouver, ISO, and other styles

6

Gniazdowski, M., and M. Czyz. "Transcription factors as targets of anticancer drugs." Acta Biochimica Polonica 46, no. 2 (1999): 255–62. http://dx.doi.org/10.18388/abp.1999_4159.

Full text

Abstract:

Several general and gene- and cell-selective transcription factors are required for specific transcription to occur. Many of them exert their functions through specific contacts either in the promoter region or at distant sequences regulating the initiation. These contacts may be altered by anticancer drugs which form non-covalent complexes with DNA. Covalent modifications of DNA by alkylating agents may prevent transcription factors from recognizing their specific sequences or may constitute multiple "unnatural" binding sites in DNA which attract the factors thus decreasing their availability

APA, Harvard, Vancouver, ISO, and other styles

7

Ali, Imran, Waseem A. Wani, Kishwar Saleem, and Ming-Fa Hsieh. "Anticancer metallodrugs of glutamic acid sulphonamides: in silico, DNA binding, hemolysis and anticancer studies." RSC Adv. 4, no. 56 (2014): 29629–41. http://dx.doi.org/10.1039/c4ra02570a.

Full text

Abstract:

In response to an increased demand for effective anticancer drugs, a series of disodium sulphonamides ofl-glutamic acid (L1–L3) was synthesized. Sulphonamides were complexed with copper(ii), nickel(ii) and ruthenium(iii) ions, separately and respectively.

APA, Harvard, Vancouver, ISO, and other styles

8

Kulkarni, Preeti, Suraksha Kadam, Disha Sharma, Manisha Mishra, and Vaidhun Bhaskar. "DNA Topoisomerases: As target for anti-cancer drugs." Indian Journal of Pharmacy and Pharmacology 9, no. 1 (2022): 13–17. http://dx.doi.org/10.18231/j.ijpp.2022.003.

Full text

Abstract:

Topoisomerase inhibitors are agents designed to interfere with the action of topoisomerase enzymes I and II. Topoisomerases are enzymes that control the changes in DNA tridimensional structure by catalyzing the breaking and rejoining of the phosphodiester backbone of DNA strands during the normal cell cycle. DNA Topoisomerases control the conformational changes in DNA topology by breaking and resealing DNA strands during normal cellular growth, that’s why these are essential enzymes. A major class of anticancer drugs acts as inhibitors of DNA Topoisomerases. This paper gives a brief review on

APA, Harvard, Vancouver, ISO, and other styles

9

ERDEM, A., H. KARADENIZ, A. CALISKAN, and A. VASEASHTA. "ELECTROCHEMICAL DNA SENSOR TECHNOLOGY FOR MONITORING OF DRUG–DNA INTERACTIONS." Nano 03, no. 04 (2008): 229–32. http://dx.doi.org/10.1142/s1793292008001064.

Full text

Abstract:

The objective of this investigation is to understand the nature and dynamics of binding small molecules to bio-macromolecules using electrochemical methods. The investigation pertaining to the design of site- and conformation-specific reagents provides a rationale for new studies of drug delivery design. Some anticancer drugs and DNA interactions have been undertaken by using a variety of techniques. Determination of interaction between DNA and DNA-targeted molecules would be valuable in the design of molecule-specific electrochemical biosensors for applications in diagnostics, development of

APA, Harvard, Vancouver, ISO, and other styles

10

Delgado, Justine L., Chao-Ming Hsieh, Nei-Li Chan, and Hiroshi Hiasa. "Topoisomerases as anticancer targets." Biochemical Journal 475, no. 2 (2018): 373–98. http://dx.doi.org/10.1042/bcj20160583.

Full text

Abstract:

Many cancer type-specific anticancer agents have been developed and significant advances have been made toward precision medicine in cancer treatment. However, traditional or nonspecific anticancer drugs are still important for the treatment of many cancer patients whose cancers either do not respond to or have developed resistance to cancer-specific anticancer agents. DNA topoisomerases, especially type IIA topoisomerases, are proved therapeutic targets of anticancer and antibacterial drugs. Clinically successful topoisomerase-targeting anticancer drugs act through topoisomerase poisoning, wh

APA, Harvard, Vancouver, ISO, and other styles

11

Babgi, Bandar A., Doaa Domyati, Magda H. Abdellattif, and Mostafa A. Hussien. "Evaluation of the Anticancer and DNA-Binding Characteristics of Dichloro(diimine)zinc(II) Complexes." Chemistry 3, no. 4 (2021): 1178–88. http://dx.doi.org/10.3390/chemistry3040086.

Full text

Abstract:

Several metal diimine complexes have been reported to possess anticancer properties. To evaluate the anticancer properties of tetrahedral zinc(II) diimine complexes, six complexes were synthesized with the general formula M(N^N)Cl2 {where M = Zn, Pt and N^N = 2,2’-biquinoline (1), 2,2’-dipyridylketone (2) and 4-((pyridine-2-ylmethylene)amino)phenol (3)}. In general, the intrinsic DNA-binding constants for the different compounds exhibited values within close proximity; the changes in the viscosity of the CT-DNA upon binding to the compounds suggest intercalation-binding mode. Molecular docking

APA, Harvard, Vancouver, ISO, and other styles

12

Xu, Xia, Yu Ke, Qi Zhang, Xiaoyu Qi, and Hongmin Liu. "DNA Binding and Cleavage Properties of Ponicidin." Tumori Journal 95, no. 3 (2009): 348–51. http://dx.doi.org/10.1177/030089160909500313.

Full text

Abstract:

Aims and background Ponicidin, an effective component isolated from Isodon rubescens, possesses anticancer properties. In the present study, we proved its ability to bind to and cleave DNA. DNA binding and cleavage properties are important for designing the rational construction of new and more efficient drugs targeted to DNA, because DNA is the biological target with which many anti-tumor drugs and potential antineoplastic agents interact. The characterization of interaction of ponicidin not only provides insights into its biology, but also gives the opportunity for developing effective thera

APA, Harvard, Vancouver, ISO, and other styles

13

Reedijk, Jan. "Increased understanding of platinum anticancer chemistry." Pure and Applied Chemistry 83, no. 9 (2011): 1709–19. http://dx.doi.org/10.1351/pac-con-10-11-03.

Full text

Abstract:

The development of a few worldwide routinely used Pt(II) coordination compounds is described from a mechanistic point of view and related to the molecular aspects of Pt-DNA binding. Mechanistic knowledge developed from these studies is applied nowadays for the design and synthesis of new bifunctional and trifunctional compounds, aimed for use as improved anticancer drugs.

APA, Harvard, Vancouver, ISO, and other styles

14

Li, Guanying, Lingli Sun, Liangnian Ji, and Hui Chao. "Ruthenium(ii) complexes with dppz: from molecular photoswitch to biological applications." Dalton Transactions 45, no. 34 (2016): 13261–76. http://dx.doi.org/10.1039/c6dt01624c.

Full text

Abstract:

The present article describes the recent advances in biological applications of the Ru-dppz systems in DNA binding, cellular imaging, anticancer drugs, phototherapy, protein aggregation detecting and chemosensors.

APA, Harvard, Vancouver, ISO, and other styles

15

Hu, Kun, Feiyan Li, Zhong Zhang, and Fupei Liang. "Synthesis of two potential anticancer copper(ii) complex drugs: their crystal structure, human serum albumin/DNA binding and anticancer mechanism." New Journal of Chemistry 41, no. 5 (2017): 2062–72. http://dx.doi.org/10.1039/c6nj02483a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Zamay, G. S., I. V. Belayanina, A. S. Zamay, et al. "DNA aptamers selection for breast cancer." Biomeditsinskaya Khimiya 62, no. 4 (2016): 411–17. http://dx.doi.org/10.18097/pbmc20166204411.

Full text

Abstract:

A method of selection of DNA aptamers to breast tumor tissue based on the use of postoperative material has been developed. Breast cancer tissues were used as the positive target; the negative targets included benign tumor tissue, adjacent healthy tissues, breast tissues from mastopathy patients, and also tissues of other types of malignant tumors. During selection a pool of DNA aptamers demonstrating selective binding to breast cancer cells and tissues and insignificant binding to breast benign tissues has been obtained. These DNA aptamers can be used for identification of protein markers, br

APA, Harvard, Vancouver, ISO, and other styles

17

Czyz, M., and M. Gniazdowski. "Actinomycin D specifically inhibits the interaction between transcription factor Sp1 and its binding site." Acta Biochimica Polonica 45, no. 1 (1998): 67–73. http://dx.doi.org/10.18388/abp.1998_4319.

Full text

Abstract:

The mode of action of many anticancer drugs involves DNA interactions. We here examine the ability of actinomycin D to alter the specific binding of transcription factors Spl and NFkappaB to their DNA sequences. Employing an electrophoretic mobility shift assay, it is shown that actinomycin D inhibits complex formation between nuclear proteins present in the extracts from stimulated human umbilical vein endothelial cells and the Sp1-binding site. Actinomycin D is also able to induce disruption of preformed DNA-protein complexes, pointing to the importance of an equilibrium of three components:

APA, Harvard, Vancouver, ISO, and other styles

18

Gurova, Katerina. "New hopes from old drugs: revisiting DNA-binding small molecules as anticancer agents." Future Oncology 5, no. 10 (2009): 1685–704. http://dx.doi.org/10.2217/fon.09.127.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Puch, Christophe Bounaix Morand du, Ewa Barbier, Alexandra Kraut, et al. "TOX4 and its binding partners recognize DNA adducts generated by platinum anticancer drugs." Archives of Biochemistry and Biophysics 507, no. 2 (2011): 296–303. http://dx.doi.org/10.1016/j.abb.2010.12.021.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Lohani, Neelam, and Moganty R. Rajeswari. "Preferential binding of anticancer drugs to triplex DNA compared to duplex DNA: a spectroscopic and calorimetric study." RSC Advances 6, no. 46 (2016): 39903–17. http://dx.doi.org/10.1039/c6ra03514k.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Wani, Tanveer A., Seema Zargar, Hamad M. Alkahtani, Nojood Altwaijry, and Lamees S. Al-Rasheed. "Anticancer Potential of Sulfonamide Moieties via In-Vitro and In-Silico Approaches: Comparative Investigations for Future Drug Development." International Journal of Molecular Sciences 24, no. 9 (2023): 7953. http://dx.doi.org/10.3390/ijms24097953.

Full text

Abstract:

Several kinds of anticancer drugs are presently commercially accessible, but low efficacy, solubility, and toxicity have reduced the overall therapeutic indices. Thus, the search for promising anticancer drugs continues. The interactions of numerous essential anticancer drugs with DNA are crucial to their biological functions. Here, the anticancer effects of N-ethyl toluene-4-sulphonamide (8a) and 2,5-Dichlorothiophene-3-sulphonamide (8b) on cell lines from breast and cervical cancer were investigated. The study also compared how these substances interacted with the hearing sperm DNA. The most

APA, Harvard, Vancouver, ISO, and other styles

22

Alshiekh, Alak, Maria Clausén, and Sofi K. C. Elmroth. "Kinetics of cisplatin binding to short r(GG) containing miRNA mimics – influence of Na+versus K+, temperature and hydrophobicity on reactivity." Dalton Transactions 44, no. 28 (2015): 12623–32. http://dx.doi.org/10.1039/c5dt00663e.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Zhou, Ying, Krzysztof Bielec, Pakorn Pasitsuparoad, and Robert Hołyst. "Single-molecule brightness analysis for the determination of anticancer drug interactions with DNA." Analyst 145, no. 20 (2020): 6600–6606. http://dx.doi.org/10.1039/d0an01108h.

Full text

Abstract:

We performed brightness analysis at a single molecular level of doxorubicin, daunorubicin, epirubicin, and idarubicin. The method was sensitive enough to confirm that the binding of drugs to the DNA occurs in two reactions.

APA, Harvard, Vancouver, ISO, and other styles

24

Alavianmehr, Mohammad M., Abolfazl Ashrafi, Reza Yousefi, et al. "Anticancer Activity Assessment and DNA Binding Properties of Two Binuclear Platinum (II) Complexes using Spectroscopic and Molecular Simulation Approaches." Anti-Cancer Agents in Medicinal Chemistry 20, no. 17 (2020): 2066–73. http://dx.doi.org/10.2174/1871520620666200705221325.

Full text

Abstract:

Background: Nowadays, the biological properties and anticancer activities of platinum-based drugs and metal coordination complexes have been receiving particular attention. These compounds have revealed clinical potential in cancer chemotherapy. Objective: In this research, two binuclear platinum complexes including [Pt2Cl2(bhq)2(μ-dppm)] (1) and [(p- MeC6H4)(bhq) Pt(μ-dppm)Pt(bhq)(CF3CO2)] (2) with bhq: benzo[h] quinolone and dppm: bis(diphenylphosphino) methane have been synthesized and evaluated for their anticancer activity against A2780 and A2780/RCIS cancer cell lines. Methods: The DNA b

APA, Harvard, Vancouver, ISO, and other styles

25

Hambley, Trevor W., Susan J. Berners-Price, Murray S. Davies, et al. "Steric Determinants of Pt/DNA Interactions and Anticancer Activity." Metal-Based Drugs 5, no. 4 (1998): 197–206. http://dx.doi.org/10.1155/mbd.1998.197.

Full text

Abstract:

Studies directed at establishing the structural features that control Pt/DNA interactions and the anticancer activity of Pt drugs are described. [H1,N15]-HSQC 2D NMR spectroscopic studies of the reactions of cisplatin with oligonucleotides containing ApG and GpA binding sites reveal dramatic differences in the rates of formation of monofunctional adducts at the two sites. When the reactant is cis-[Pt(NH3)2(OH2)2]2+ no such differences are observed suggesting that outer-sphere interactions between the reactant and the oligonucleotide may play a substantial role in determining the rates. Rates o

APA, Harvard, Vancouver, ISO, and other styles

26

Gmeiner, W. H. "NMR Spectroscopy as A Tool to Investigate the Structural Basis of Anticancer Drugs." Current Medicinal Chemistry 5, no. 2 (1998): 115–35. http://dx.doi.org/10.2174/0929867305666220314202136.

Full text

Abstract:

NMR spectroscopy has been shown to be useful in determining the structures of nucleic acid fragments in solution. Over the last several years NMR spectroscopy, in conjunction with restrained molecular dynamics, has been employed to understand the 3D structures of a number of anticancer drugs and to rationalize their DNA binding behavior. In this review we address the methodologies used most frequently to determine nucleic acid structures in solution. In subsequent sections, we examine how these methods have been applied to rationalize the activities of a number of anticancer agents that target

APA, Harvard, Vancouver, ISO, and other styles

27

Kurniawan, Yehezkiel Steven, Krisfian Tata Aneka Priyangga, Jumina, et al. "An Update on the Anticancer Activity of Xanthone Derivatives: A Review." Pharmaceuticals 14, no. 11 (2021): 1144. http://dx.doi.org/10.3390/ph14111144.

Full text

Abstract:

The annual number of cancer deaths continues increasing every day; thus, it is urgent to search for and find active, selective, and efficient anticancer drugs as soon as possible. Among the available anticancer drugs, almost all of them contain heterocyclic moiety in their chemical structure. Xanthone is a heterocyclic compound with a dibenzo-γ-pyrone framework and well-known to have “privileged structures” for anticancer activities against several cancer cell lines. The wide anticancer activity of xanthones is produced by caspase activation, RNA binding, DNA cross-linking, as well as P-gp, ki

APA, Harvard, Vancouver, ISO, and other styles

28

Hoseini, Leila, and Azar Bagheri. "Catalytic properties of plate-like cadmium oxide nanoparticles in removal of sulfathiazole with anticancer activity." Main Group Metal Chemistry 41, no. 3-4 (2018): 121–28. http://dx.doi.org/10.1515/mgmc-2018-0025.

Full text

Abstract:

Abstract The study of the interaction of drugs with DNA is very exciting and significant not only for understanding the mechanism of the interaction but also for the design of new drugs. Here, we report the results of Fourier transform infrared (FT-IR) and ultraviolet (UV)-visible spectroscopy studies to determine the external binding modes of sulfathiazole (STZ), and the binding constant and stability of the STZ-DNA complex in aqueous solution. The results of absorption spectra showed that the interaction of STZ-DNA is weak because there is only a hyperchromic effect. A hyperchromic effect re

APA, Harvard, Vancouver, ISO, and other styles

29

Çeşme, Mustafa, Aysegul Gölcü, and Ibrahim Demirtaş. "New metal based drugs: Spectral, electrochemical, DNA-binding, surface morphology and anticancer activity properties." Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 135 (January 2015): 887–906. http://dx.doi.org/10.1016/j.saa.2014.06.144.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Deng, Chunqiang, and Lixin Zhou. "Binding of ansa- and non-ansa-titanocene anticancer drugs to DNA: a DFT study." Structural Chemistry 21, no. 4 (2010): 735–44. http://dx.doi.org/10.1007/s11224-010-9603-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Sen, Subhadeep, Nilkanta Chowdhury, Tae-Wan Kim, et al. "Anticancer, Antibacterial, Antioxidant, and DNA-Binding Study of Metal-Phenalenyl Complexes." Bioinorganic Chemistry and Applications 2022 (April 14, 2022): 1–15. http://dx.doi.org/10.1155/2022/8453159.

Full text

Abstract:

Phenalenyl (PLY)-based metal complexes are a new addition to the metal complex family. Various applications of metal-based phenalenyl complexes (metal-PLY) have been reported, such as catalyst, quantum spin simulators, spin electronic devices, and molecular conductors, but the biological significance of metal-PLY (metal = Co(II), Mn(III), Ni(II), Fe(III), and Al(III)) systems has yet to be explored. In this study, the anticancer properties of such complexes were investigated in ovarian cancer cells (SKOV3 and HEY A8), and the cytotoxicity was comparable to that of other platinum-based drugs. A

APA, Harvard, Vancouver, ISO, and other styles

32

Liu, Jingli, Hui Guo, Jing Zhou, et al. "Evodiamine and Rutaecarpine as Potential Anticancer Compounds: A Combined Computational Study." International Journal of Molecular Sciences 23, no. 19 (2022): 11513. http://dx.doi.org/10.3390/ijms231911513.

Full text

Abstract:

Evodiamine (EVO) and rutaecarpine (RUT) are the main active compounds of the traditional Chinese medicinal herb Evodia rutaecarpa. Here, we fully optimized the molecular geometries of EVO and RUT at the B3LYP/6-311++G (d, p) level of density functional theory. The natural population analysis (NPA) charges, frontier molecular orbitals, molecular electrostatic potentials, and the chemical reactivity descriptors for EVO and RUT were also investigated. Furthermore, molecular docking, molecular dynamics simulations, and the analysis of the binding free energies of EVO and RUT were carried out again

APA, Harvard, Vancouver, ISO, and other styles

33

Fox, M. E., B. J. Feldman, and G. Chu. "A novel role for DNA photolyase: binding to DNA damaged by drugs is associated with enhanced cytotoxicity in Saccharomyces cerevisiae." Molecular and Cellular Biology 14, no. 12 (1994): 8071–77. http://dx.doi.org/10.1128/mcb.14.12.8071-8077.1994.

Full text

Abstract:

DNA photolyase binds to and repairs cyclobutane pyrimidine dimers induced by UV radiation. Here we demonstrate that in the yeast Saccharomyces cerevisiae, photolyase also binds to DNA damaged by the anticancer drugs cis-diamminedichloroplatinum (cis-DDP) and nitrogen mustard (HN2) and by the alkylating agent N-methyl-N'-nitro-N-nitrosoguanidine (MNNG). Surprisingly, mutations in photolyase were associated with resistance of yeast cells to cis-DDP, MNNG, 4-nitroquinoline oxide (4NQO), and HN2. Transformation of yeast photolyase mutants with the photolyase gene increased sensitivity to these age

APA, Harvard, Vancouver, ISO, and other styles

34

Fox, M. E., B. J. Feldman, and G. Chu. "A novel role for DNA photolyase: binding to DNA damaged by drugs is associated with enhanced cytotoxicity in Saccharomyces cerevisiae." Molecular and Cellular Biology 14, no. 12 (1994): 8071–77. http://dx.doi.org/10.1128/mcb.14.12.8071.

Full text

Abstract:

DNA photolyase binds to and repairs cyclobutane pyrimidine dimers induced by UV radiation. Here we demonstrate that in the yeast Saccharomyces cerevisiae, photolyase also binds to DNA damaged by the anticancer drugs cis-diamminedichloroplatinum (cis-DDP) and nitrogen mustard (HN2) and by the alkylating agent N-methyl-N'-nitro-N-nitrosoguanidine (MNNG). Surprisingly, mutations in photolyase were associated with resistance of yeast cells to cis-DDP, MNNG, 4-nitroquinoline oxide (4NQO), and HN2. Transformation of yeast photolyase mutants with the photolyase gene increased sensitivity to these age

APA, Harvard, Vancouver, ISO, and other styles

35

Kumar, Santosh, and Michael Y. Sherman. "Resistance to TOP-1 Inhibitors: Good Old Drugs Still Can Surprise Us." International Journal of Molecular Sciences 24, no. 8 (2023): 7233. http://dx.doi.org/10.3390/ijms24087233.

Full text

Abstract:

Irinotecan (SN-38) is a potent and broad-spectrum anticancer drug that targets DNA topoisomerase I (Top1). It exerts its cytotoxic effects by binding to the Top1-DNA complex and preventing the re-ligation of the DNA strand, leading to the formation of lethal DNA breaks. Following the initial response to irinotecan, secondary resistance is acquired relatively rapidly, compromising its efficacy. There are several mechanisms contributing to the resistance, which affect the irinotecan metabolism or the target protein. In addition, we have demonstrated a major resistance mechanism associated with t

APA, Harvard, Vancouver, ISO, and other styles

36

Gul, Asghari, Zareen Akhter, Fouzia Perveen, Saima Kalsoom, Farzana L. Ansari, and Muhammad Siddiq. "Molecular Docking and Quantitative Structure Activity Relationship (QSAR) Studies of Some Newly Synthesized Poly (Azomethine) Esters." International Journal of Polymer Science 2019 (January 17, 2019): 1–10. http://dx.doi.org/10.1155/2019/2103891.

Full text

Abstract:

Molecular docking procedure is well known for the investigation of small molecules; however, for macromolecules, it has attained limited success so far. Thus, in an attempt, a series of poly (azomethine) esters was synthesized in a laboratory, and their model oligomer units were studied by computer-aided computational MOE software package to investigate, specifically, binding modes that could influence their anticancer activities. Poly (azomethine) ester (PAME) was prepared by solution phase polycondensation of a preformed Schiff base (SB) 4-((4-(4-(4-hydroxybenzylideneamino)phenoxy)phenylimin

APA, Harvard, Vancouver, ISO, and other styles

37

Akrami, Hamidreza, Bibi Fatemeh Mirjalili, Omidreza Firuzi, et al. "Cytotoxic Activity and DNA Binding Property of New Aminopyrimidine Derivatives." Letters in Drug Design & Discovery 17, no. 5 (2020): 640–54. http://dx.doi.org/10.2174/1570180816666190712102119.

Full text

Abstract:

Background: Chromene and anilinopyrimidine heterocyclics are attractive anticancer compounds that have inspired many researchers to design novel derivatives bearing improved anticancer activity. Methods: A series of pyrimidine-fused benzo[f]chromene derivatives 6a-x were synthesized as anticancer hybrids of 1H-benzo[f]chromenes and anilinopyrimidines. The inhibitory activity of the synthesized compounds 6a-x against cell viability of human chronic myelogenous leukemia (K562), human acute lymphoblastic leukemia (MOLT-4) and human breast adenocarcinoma (MCF-7) cell lines was evaluated using MTT

APA, Harvard, Vancouver, ISO, and other styles

38

Bailly, Christian, and Gérard Vergoten. "Interaction of Camptothecin Anticancer Drugs with Ribosomal Proteins L15 and L11: A Molecular Docking Study." Molecules 28, no. 4 (2023): 1828. http://dx.doi.org/10.3390/molecules28041828.

Full text

Abstract:

The antitumor drug topotecan (TPT) is a potent inhibitor of topoisomerase I, triggering DNA breaks lethal for proliferating cancer cells. The mechanism is common to camptothecins SN38 (the active metabolite of irinotecan) and belotecan (BLT). Recently, TPT was shown to bind the ribosomal protein L15, inducing an antitumor immune activation independent of topoisomerase I. We have modeled the interaction of four camptothecins with RPL15 derived from the 80S human ribosome. Two potential drug-binding sites were identified at Ile135 and Phe129. SN38 can form robust RPL15 complexes at both sites, w

APA, Harvard, Vancouver, ISO, and other styles

39

Yao, Lina, Yanjie Li, Zhenzhong Zuo, et al. "Studying the Interaction between Bendamustine and DNA Molecule with SERS Based on AuNPs/ZnCl2/NpAA Solid-State Substrate." International Journal of Molecular Sciences 24, no. 17 (2023): 13517. http://dx.doi.org/10.3390/ijms241713517.

Full text

Abstract:

Bendamustine (BENDA) is a bifunctional alkylating agent with alkylating and purinergic antitumor activity, which exerts its anticancer effects by direct binding to DNA, but the detailed mechanism of BENDA–DNA interaction is poorly understood. In this paper, the interaction properties of the anticancer drug BENDA with calf thymus DNA (ctDNA) were systematically investigated based on surface-enhanced Raman spectroscopy (SERS) technique mainly using a novel homemade AuNPs/ZnCl2/NpAA (NpAA: nano porous anodic alumina) solid-state substrate and combined with ultraviolet–visible spectroscopy and mol

APA, Harvard, Vancouver, ISO, and other styles

40

Hannon, Michael J. "Metal-based anticancer drugs: From a past anchored in platinum chemistry to a post-genomic future of diverse chemistry and biology." Pure and Applied Chemistry 79, no. 12 (2007): 2243–61. http://dx.doi.org/10.1351/pac200779122243.

Full text

Abstract:

The field of metal-based anticancer drugs was initiated by cisplatin, one of the leading agents in clinical use. Cisplatin acts by binding to DNA and forming 1,2 intrastrand cross-links. Its importance is reflected by the fact that it is estimated that 50-70 % of cancer patients are treated with a platinum drug [7]. For some time, molecular designs in the metallo-drug field remained obdurately anchored in cis-diamine platinum(II) chemistry, but now the field is evolving rapidly with a variety of alternate and very diverse designs being explored. These designs give rise to new spectra of activi

APA, Harvard, Vancouver, ISO, and other styles

41

Rodrigues, Edson Silvio Batista, Isaac Yves Lopes de Macêdo, Giovanna Nascimento de Mello e. Silva, et al. "DNA-Based Electrodes and Computational Approaches on the Intercalation Study of Antitumoral Drugs." Molecules 26, no. 24 (2021): 7623. http://dx.doi.org/10.3390/molecules26247623.

Full text

Abstract:

The binding between anticancer drugs and double-stranded DNA (dsDNA) is a key issue to understand their mechanism of action, and many chemical methods have been explored on this task. Molecular docking techniques successfully predict the affinity of small molecules into the DNA binding sites. In turn, various DNA-targeted drugs are electroactive; in this regard, their electrochemical behavior may change according to the nature and strength of interaction with DNA. A carbon paste electrode (CPE) modified with calf thymus ds-DNA (CPDE) and computational methods were used to evaluate the drug–DNA

APA, Harvard, Vancouver, ISO, and other styles

42

Guin, Partha Sarathi, Piyal Das, Saurabh Das, and Parikshit Chandra Mandal. "Interaction of Calf Thymus DNA with the Ni(II) Complex of Sodium 1,4-Dihydroxy-9,10-Anthraquinone-2-Sulphonate: A Novel Method of Analysis Using Cyclic Voltammetry." International Journal of Electrochemistry 2012 (2012): 1–10. http://dx.doi.org/10.1155/2012/183745.

Full text

Abstract:

Hydroxy-9,10-anthraquinones are cheaper alternatives to anthracycline drugs. They closely resemble anthracycline drugs both from a structural and functional viewpoint. Electrochemical behavior of the Ni(II) complex (Na2[Ni(NaLH)2Cl2]⋅2H2O) of sodium 1,4-dihydroxy-9,10-anthraquinone-2-sulphonate (NaLH2), analogue of the core unit of anthracycline anticancer drugs, was studied at physiological pH using cyclic voltammetry. The Ni(II) complex of sodium 1,4-dihydroxy-9,10-anthraquinone-2-sulphonate undergoes diffusion-controlled one-electron reduction that enables performing an electrochemical stud

APA, Harvard, Vancouver, ISO, and other styles

43

BAL, Mustafa, and Ayşegül KÖSE. "Crystal Structure and DNA Binding Properties of A Sulfide Bridged Dimeric Schiff Base Compound." Osmaniye Korkut Ata Üniversitesi Fen Bilimleri Enstitüsü Dergisi 6, no. 1 (2023): 818–31. http://dx.doi.org/10.47495/okufbed.1180912.

Full text

Abstract:

In this study, a new 4,4'-Diaminodiphenyl sulfide-based Schiff base compound [6,6'-((1E,1'E)-((thiobis (4,1-phenylene)) bis(azaneylylidene)) bis(methaneylylidene)) bis(3-(diethylamino) phenol) (A)], which is known to have very good biological activity and form the basis of anticancer drugs, was successfully synthesized. The spectral properties and DNA binding properties of the Schiff base compound obtained within the scope of the study were investigated. The structure of the synthesized compound was characterized by UV–Vis, FT-IR, 1H NMR, 13C NMR and Photoluminescence spectroscopy. However, th

APA, Harvard, Vancouver, ISO, and other styles

44

Elsayed, Shadia A., Entsar A. Saad, and Sahar I. Mostafa. "Development of New Potential Anticancer Metal Complexes Derived from 2-Hydrazinobenzothiazole." Mini-Reviews in Medicinal Chemistry 19, no. 11 (2019): 913–22. http://dx.doi.org/10.2174/1389557518666181017143548.

Full text

Abstract:

Background: Due to the side effects of clinically approved anticancer drugs there is a great need to explore and develop new metal-based anticancer drug molecules of high efficiency with less or no side effects. Objective: To synthesize new metal complexes of 2-hydrazinobenzothiazole (hbt) and to investigate their potential anticancer characteristics. Methods: New five complexes; [VO(hbt)2SO4].4H2O (1), [Ru(hbt)2Cl3(H2O)] (2), [M(hbt)2Cl2] [M(II) = Pd (3), Pt (4)] and [Ag(hbt)2].NO3 (5) were prepared and their structure was investigated by means of FTIR, 1H NMR, ESI-MS and UV-Vis spectra, elem

APA, Harvard, Vancouver, ISO, and other styles

45

Defant, Andrea, Paolo Gatti, Alessandro Poli, et al. "DNA-Binding Properties of Cytotoxic Naphtindolizinedione-Carboxamides Acting as Type II Topoisomerase Inhibitors. A Combined In Silico and Experimental Study." Chemistry Proceedings 3, no. 1 (2020): 96. http://dx.doi.org/10.3390/ecsoc-24-08103.

Full text

Abstract:

Some clinically-used anticancer drugs are DNA intercalators acting as topoisomerase (Topo) IIα poisons in tumor cells highly expressing the enzyme. Synthetic naphtindolizinedione-carboxamides, previously designed as potential antitumor agents and showing relevant cytotoxic activities in vitro, have been now evaluated for their DNA-binding and inhibition of human Topo IIα, in comparison with the drug mitoxantrone. Docking calculation of each synthetic molecule as ligand with the CGCGAATTCGCG oligonucleotide model showed a stable intercalation in the DNA cut inside the enzyme. Moreover, molecula

APA, Harvard, Vancouver, ISO, and other styles

46

Ozturk, Ozum, Esin Aki-Yalcin, Ismail Yalcin, and Renate Grifitth. "Insight into Mechanism of Action of Anticancer Benzazoles." Current Topics in Medicinal Chemistry 20, no. 23 (2020): 2056–69. http://dx.doi.org/10.2174/1568026620666200819152108.

Full text

Abstract:

Background: Targeting the DNA topoisomerase II enzyme (topo II) is a promising anticancer treatment approach. TopoII controls and modifies the topological states of DNA and plays key roles in DNA replication, transcription, and chromosome segregation. The DNA binding and cleavage domain is one of the active sites of this enzyme. It is known that topoisomerase inhibitors, also known as topoisomerase poisons, bind to the transient enzyme-DNA complex and inhibit the religation of DNA, generating single- and double-stranded breaks that harm the integrity of the genome. This ultimately leads to the

APA, Harvard, Vancouver, ISO, and other styles

47

Yang, Pin, and Maolin Guo. "Interaction of Some Non-Platinum Metal Anticancer Complexes With Nucleotides and DNA and The Two-Pole Complementary Principle (TPCP) Arising Therefrom." Metal-Based Drugs 5, no. 1 (1998): 41–58. http://dx.doi.org/10.1155/mbd.1998.41.

Full text

Abstract:

The binding modes of some non-platinum metal anticancer complexes, Cp2TiCl2, Cp2ZrCl2, (CH3)2SnCl2, (C2H5)2SnCl2, (C2H5)2SnCl2(phen) (phen=Phenanthroline) and cis-RuIICl2(DMSO)3 (DMSO) (cis-RDT) with nucleotides and DNA in aqueous solution at physiological pH values were investigated by various modern techniques. 5'-dGMP with Cp2TiCl2 or cis-RDT forms chelate complexes in which both N7 and phosphate of dGMP bind to the metal center. Whereas Cp2ZrCl2 and all the diorganotin compounds can bind dGMP only via the phosphate group. The investigations of the interactions between Cp2TiCl2 or (C2H5)2Sn

APA, Harvard, Vancouver, ISO, and other styles

48

Bhat, Satish S., Vidyanand K. Revankar, Vijay Kumbar, Kishore Bhat, and Vitthal A. Kawade. "Synthesis, crystal structure and biological properties of a cis-dichloridobis(diimine)copper(II) complex." Acta Crystallographica Section C Structural Chemistry 74, no. 2 (2018): 146–51. http://dx.doi.org/10.1107/s2053229617018551.

Full text

Abstract:

The mechanisms of interaction of inorganic complexes with DNA are important in the design and development of new metal-based drug molecules. The limitations of cis-platin have encouraged the design and development of new metal-based target-specific anticancer drugs having reduced side effects. The complex cis-dichloridobis(1,2,5-thiadiazolo[3,4-f][1,10]phenanthroline-κ2 N 1,N 10)copper(II), [CuCl2(C12H6N4S)2], has been synthesized and characterized. The complex crystallizes in the monoclinic space group C2/c. The covalent binding of the complex with DNA was studied by absorption spectroscopy.

APA, Harvard, Vancouver, ISO, and other styles

49

Mansouri, Farangis, Luc Patiny, Daniel Ortiz, et al. "Simultaneous mass spectrometry analysis of cisplatin with oligonucleotide-peptide mixtures: implications for the mechanism of action." JBIC Journal of Biological Inorganic Chemistry 27, no. 2 (2022): 239–48. http://dx.doi.org/10.1007/s00775-022-01924-9.

Full text

Abstract:

AbstractAlthough genomic DNA is the primary target of anticancer platinum-based drugs, interactions with proteins also play a significant role in their overall activity. In this study, competitive binding of cisplatin with an oligonucleotide and two peptides corresponding to segments of H2A and H2B histone proteins was investigated by mass spectrometry. Following the determination of the cisplatin binding sites on the oligonucleotide and peptides by tandem mass spectrometry, competitive binding was studied and transfer of platinum fragments from the platinated peptides to the oligonucleotide e

APA, Harvard, Vancouver, ISO, and other styles

50

Zhang, Si-Qi, Li-Hua Gao, Hua Zhao, and Ke-Zhi Wang. "Recent Progress in Polynuclear Ruthenium Complex-Based DNA Binders/Structural Probes and Anticancer Agents." Current Medicinal Chemistry 27, no. 22 (2020): 3735–52. http://dx.doi.org/10.2174/0929867326666181203143422.

Full text

Abstract:

Ruthenium complexes have stood out by several mononuclear complexes which have entered into clinical trials, such as imidazolium [trans-RuCl4(1H-imidazole)(DMSO-S)] (NAMI-A) and ([Ru(II)(4,4&#039;-dimethyl-2,2&#039;-bipyridine)2-(2(2&#039;-,2&#039;&#039;:5&#039;&#039;,2&#039;&#039;&#039;-terthiophene)-imidazo[4,5-f] [1,10]phenanthroline)] 2+) (TLD-1433), opening a new avenue for developing promising ruthenium-based anticancer drugs alternative to Cisplatin. Polynuclear ruthenium complexes were reported to exhibit synergistic and/or complementary effects:

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!